Lexicon Pharmaceuticals Inc LXRX:NASDAQ

Last Price$3.17NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$2.85 (8)
Ask (Size)$3.15 (3)
Day Low / HighN/A - N/A
Volume3.3 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/12/2022


Lexicon Pharmaceuticals Inc ( NASDAQ )

Price: $3.17
Change: +0.41 (14.86%)
Volume: 3.3 M
4:00PM ET 8/12/2022

Vanda Pharmaceuticals Inc ( NASDAQ )

Price: $10.41
Change: +0.11 (1.07%)
Volume: 369.8 K
4:00PM ET 8/12/2022

Aerie Pharmaceuticals Inc ( NASDAQ )

Price: $11.57
Change: +0.48 (4.33%)
Volume: 492.8 K
4:00PM ET 8/12/2022

Protagonist Therapeutics Inc ( NASDAQ )

Price: $11.40
Change: +1.00 (9.62%)
Volume: 957.5 K
4:00PM ET 8/12/2022

IDEAYA Biosciences Inc ( NASDAQ )

Price: $15.65
Change: +0.73 (4.89%)
Volume: 186.9 K
4:00PM ET 8/12/2022

Read more news Recent News

Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage
12:11PM ET 8/12/2022 MT Newswires

Lexicon Pharmaceuticals (LXRX) shares rose more than 12% in Friday trade after Piper Sandler initiated the company's coverage with an overweight rating and...

--Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target
8:08AM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Insider Buy: Lexicon Pharmaceuticals
4:18PM ET 8/01/2022 MT Newswires

Raymond Debbane, Director, on August 01, 2022, executed a purchase for 982,600 shares in Lexicon Pharmaceuticals (LXRX) for $2,456,500. Following the Form...

Lexicon Pharmaceuticals Plans Stock Offering to Fund Development, Launch of Heart-Failure Treatment; Shares Sink After Hours
5:47PM ET 7/27/2022 MT Newswires

Lexicon Pharmaceuticals (LXRX) late Wednesday said it commenced an underwritten public offering to sell shares of its common stock, and that it will grant...

Company Profile

Business DescriptionLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX. View company web site for more details
Address2445 Technology Forest Boulevard
The Woodlands, Texas 77381-1160
Number of Employees202
Recent SEC Filing08/09/20224
Chief Executive Officer & DirectorLonnel Coats
President & Chief Financial OfficerJeffrey L. Wade
Chief Medical Officer & Senior Vice PresidentCraig B. Granowitz
Secretary, Senior Vice President & General CounselBrian T. Crum

Company Highlights

Price Open$2.90
Previous Close$2.76
52 Week Range$1.31 - 6.33
Market Capitalization$582.1 M
Shares Outstanding183.6 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.65
Beta vs. S&P 500N/A
Revenue$63.2 M
Net Profit Margin-88,803.67%
Return on Equity-93.58%

Analyst Ratings as of 08/11/2022

Consensus RecommendationConsensus Icon
Powered by Factset